A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic ce...
A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma
About this item
Full title
Author / Creator
Xia, Lingfang , Zhou, Qi , Gao, Yunong , Hu, Wenjing , Lou, Ge , Sun, Hong , Zhu, Jianqing , Shu, Jin , Zhou, Xianfeng , Sun, Rong and Wu, Xiaohua
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
This phase 2 study assesses the efficacy and safety of camrelizumab (an anti-PD-1 antibody) plus famitinib (anti-angiogenic agent) in women with pretreated recurrent or metastatic cervical cancer (ClinicalTrials.gov NCT03827837). Patients with histologically or cytologically confirmed cervical squamous cell carcinoma experiencing relapse or progres...
Alternative Titles
Full title
A multicenter phase 2 trial of camrelizumab plus famitinib for women with recurrent or metastatic cervical squamous cell carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_b68826bcc1284eef9a80d3a0217d0034
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b68826bcc1284eef9a80d3a0217d0034
Other Identifiers
ISSN
2041-1723
E-ISSN
2041-1723
DOI
10.1038/s41467-022-35133-4
